Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer

Globe Newswire - Press Release

All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here

-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies --

SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced that it has enrolled the first patient in a phase 2 clinical trial of sapanisertib (CB-228) in patients with relapsed/refractory NRF2 (NFE2L2)-mutated squamous non-small cell lung cancer (sqNSCLC).

Read more at globenewswire.com

Related Symbols

Symbol Last Chg %Chg
CALA 0.0002 unch unch
Calithera Biosci Com

Most Popular News

AI engineer working on laptop by ART STOCK CREATIVE via Shutterstock 1
Nvidia vs. Palantir: Which Stock Is the Better Long-Term AI Buy?
A colorful concept image of a scoring system_ Image by Who is Danny via Shutterstock_ 2
The Saturday Spread: 3 Stocks Flashing High-Probability Trading Setups to Consider This Week
DIVIDENDS text on documents with graphs by Jittawit21 via Shutterstock 3
3 High-Yield Stocks to Invest in Oracle’s AI Growth with Less Volatility
OPTIONS TRADING open book on table by One Photo via Shutterstock 4
Tesla, Netflix, and ON Semiconductor: 3 Unusually Active Cash-Secured Put Options to Sell Now
Salesforce Inc HQ building-by JHVEPhoto via Shutterstock 5
Salesforce Generates Strong Free Cash Flow - CRM Could Be 23% Too Cheap
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot